Insider Transactions in Q1 2024 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2024
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
34,811
-6.56%
|
$174,055
$5.6 P/Share
|
|
Mar 06
2024
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
126,981
-7.7%
|
$634,905
$5.6 P/Share
|
|
Mar 06
2024
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
57,745
-11.51%
|
$288,725
$5.6 P/Share
|
|
Mar 06
2024
|
Scott Michael Habig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,777
-3.61%
|
$88,885
$5.6 P/Share
|
|
Mar 06
2024
|
Matthew Maxwell Donley EVP, Ops & Strategy |
SELL
Open market or private sale
|
Direct |
40,665
-6.51%
|
$203,325
$5.51 P/Share
|
|
Feb 27
2024
|
Volker Knappertz EVP, Research and Development |
SELL
Open market or private sale
|
Direct |
4,930
-1.52%
|
$29,580
$6.1 P/Share
|
|
Feb 20
2024
|
Volker Knappertz EVP, Research and Development |
SELL
Open market or private sale
|
Direct |
25,146
-7.2%
|
$125,730
$5.48 P/Share
|
|
Feb 20
2024
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
216,666
+25.75%
|
-
|
|
Feb 20
2024
|
Scott Michael Habig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,867
-3.12%
|
$79,335
$5.48 P/Share
|
|
Feb 20
2024
|
Scott Michael Habig Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
195,512
+27.78%
|
-
|
|
Feb 20
2024
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
661,538
+28.63%
|
-
|
|
Feb 20
2024
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
196,153
+26.99%
|
-
|
|
Feb 20
2024
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
194,230
+27.91%
|
-
|